📄 What This Document Is

This is a 6-K report filed with the SEC. It's a current report used by foreign companies (like Cayman Islands-based Prenetics) to announce major events to investors. This specific filing is a major press release announcing a multi-year global partnership with NBA superstar Giannis Antetokounmpo for its supplement brand, IM8. It signals a significant marketing and growth move.

🏀 The Big News: Giannis Joins The Team

👉 In simple terms, Prenetics' supplement company, IM8, has partnered with one of the world's most famous basketball players, Giannis Antetokounmpo. This isn't just a typical endorsement deal; Giannis is becoming a shareholder in Prenetics (NASDAQ: PRE), the parent company.

• The Deal: A multi-year global partnership. Giannis becomes a "Global Partner" of IM8.
• The Unique Angle: He is taking 100% equity (shares) in the company instead of a cash payment. This aligns his financial success directly with that of other shareholders.
• Why He's Valuable: Giannis has over 35 million followers across social media and the NBA is broadcast in 215 countries, giving IM8 a massive channel for global expansion.

📈 The IM8 Growth Story: Lightning Fast

The filing highlights the explosive growth of IM8, which was co-founded with David Beckham.

• Speed to $100M: IM8 reached $100 million in annualized recurring revenue (ARR) in just 11 months after its December 2024 launch. The company calls this "unprecedented in the supplement industry."
• Current Scale: Over 22 million servings delivered, 750,000+ customer purchases across 31 countries.
• 2026 Revenue Projection: The company forecasts IM8 will generate between $180 million and $200 million in revenue for the full year 2026.

⚖️ Why This Matters: Three Strategic Priorities

For Prenetics shareholders, this partnership is designed to tackle key goals:

1. Market Expansion: Giannis's core fanbase (ages 18-34) is a demographic where IM8 is "under-scaled." The NBA's global reach opens direct channels into new markets.
2. Cross-Sport Credibility: IM8 now has equity-holding partners from four major sports: Football (Beckham), Tennis (Aryna Sabalenka), Formula 1 (Ollie Bearman), and Basketball (Giannis). This builds immense brand trust.
3. Shared Alignment: Like Giannis, Prenetics management has its "skin in the game." The company mentions up to $42.75 million in combined share commitments, including a $40 million share repurchase program and $2.75 million in executive stock purchases.

💰 Financial Health Check

The filing provides key details on the company's financial position to support this growth.

• Liquidity (as of March 1, 2026): The company states a total adjusted liquidity of approximately $160 million on a zero-debt basis.
• What's in that $160M?
  • Cash: $93.0 million
  • Financial Assets: ~$29.3 million
  • Digital Assets: ~$34.2 million
  • Funds in Escrow: $7.3 million ($6.3M + $1.0M from past sales)
• Profitability Target: The company aims to hit adjusted EBITDA profitability by Q4 2027.

🧪 The Product: Science-Backed Supplements

IM8's pitch is premium, science-backed daily nutrition.

• Flagship Product: Daily Ultimate Essentials PRO - a powder with 90 premium ingredients at clinical doses.
• Other Key Product: Daily Ultimate Longevity - targets the "12 hallmarks of aging."
• Key Credentials: Products are NSF Certified for Sport and backed by a 12-week randomized controlled trial showing benefits in energy, digestion, sleep, and focus.
• Future Trials: The company plans to start multiple new clinical trials in 2026, with results expected by year-end.

🔮 What's Next & The Broader Picture

👍 Strengths:

• Unmatched Athlete Roster: Four global sports icons as shareholders is a powerful marketing and credibility tool.
• Proven Rapid Growth: The $100M ARR milestone in 11 months demonstrates strong product-market fit.
• Strong Balance Sheet: Significant liquidity ($160M) with no debt provides a solid runway for growth.

⚠️ Risks to Consider:

• Execution Risk: Translating this star power into sustained, profitable sales across dozens of new countries is a major challenge.
• Competitive Market: The health supplement space is crowded and competitive.
• Path to Profitability: While revenue is growing fast, achieving profitability (targeted for late 2027) is the next critical hurdle.

🧠 The Analogy

Think of Prenetics building a "super-team" in the business world. Just like an NBA team trades for a superstar like Giannis to win a championship, Prenetics is "acquiring" Giannis as a shareholder-partner to win in the global health market. His equity stake means he only wins if the company and its other shareholders win too.

📇 Key Contacts & People

• Danny Yeung: CEO of Prenetics, co-founder of IM8.
• Giannis Antetokounmpo: NBA Champion, new Global Partner and Shareholder.
• Investor Relations Contact: [email protected]
• Investor Relations Inquiries: [email protected]
• Angela Cheung: Investor Relations / Corporate Finance, [email protected]

🧩 Final Takeaway

Prenetics is leveraging its hyper-growth supplement brand, IM8, and a unique equity-based partnership model to attract world-class athlete-investors. The signing of Giannis Antetokounmpo is a major strategic move to accelerate global expansion, funded by a strong, debt-free balance sheet, with the ultimate goal of building a dominant, profitable "generational brand" in consumer health.